Multiple Myeloma

The efficacy of high-dose chemotherapy in multiple myeloma has led to inclusion of autologous HSCT as part of its initial therapy.100101 Due to unique biologic characteristics, there are clinical data demonstrating that the inclusion of more than one cycle of high-dose chemotherapy with autologous HSCT may improve upon the results of a single transplant.102 Although there is clear evidence of a GVL effect against multiple myeloma, a tumor-specific antigen has not been identified. The use of myeloablative allogeneic HSCT is controversial, as they have been associated with a high mortality rate.103 Results of allogeneic HSCT in multiple myeloma have been improved with the use of non-myeloablative conditioning regimens.104

0 0

Post a comment